Marks JD - Search Results

1

Avidity-mediated enhancement of in vivo tumor targeting by single-chain Fv dimers.

Adams GP, Tai MS, McCartney JE, Marks JD, Stafford WF 3rd, Houston LL, Huston JS, Weiner LM. Adams GP, et al. Among authors: marks jd. Clin Cancer Res. 2006 Mar 1;12(5):1599-605. doi: 10.1158/1078-0432.CCR-05-2217. Clin Cancer Res. 2006. PMID: 16533787

2

Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors.

Rudnick SI, Lou J, Shaller CC, Tang Y, Klein-Szanto AJ, Weiner LM, Marks JD, Adams GP. Rudnick SI, et al. Among authors: marks jd. Cancer Res. 2011 Mar 15;71(6):2250-9. doi: 10.1158/0008-5472.CAN-10-2277. Cancer Res. 2011. PMID: 21406401 Free PMC article.

3

Effective treatment of established human breast tumor xenografts in immunodeficient mice with a single dose of the alpha-emitting radioisotope astatine-211 conjugated to anti-HER2/neu diabodies.

Robinson MK, Shaller C, Garmestani K, Plascjak PS, Hodge KM, Yuan QA, Marks JD, Waldmann TA, Brechbiel MW, Adams GP. Robinson MK, et al. Among authors: marks jd. Clin Cancer Res. 2008 Feb 1;14(3):875-82. doi: 10.1158/1078-0432.CCR-07-1250. Clin Cancer Res. 2008. PMID: 18245551 Free PMC article.

4

A single treatment of yttrium-90-labeled CHX-A"-C6.5 diabody inhibits the growth of established human tumor xenografts in immunodeficient mice.

Adams GP, Shaller CC, Dadachova E, Simmons HH, Horak EM, Tesfaye A, Klein-Szanto AJ, Marks JD, Brechbiel MW, Weiner LM. Adams GP, et al. Among authors: marks jd. Cancer Res. 2004 Sep 1;64(17):6200-6. doi: 10.1158/0008-5472.CAN-03-2382. Cancer Res. 2004. PMID: 15342405

5

Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody.

Robinson MK, Doss M, Shaller C, Narayanan D, Marks JD, Adler LP, González Trotter DE, Adams GP. Robinson MK, et al. Among authors: marks jd. Cancer Res. 2005 Feb 15;65(4):1471-8. doi: 10.1158/0008-5472.CAN-04-2008. Cancer Res. 2005. PMID: 15735035

6

Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies.

Adams GP, Schier R, Marshall K, Wolf EJ, McCall AM, Marks JD, Weiner LM. Adams GP, et al. Among authors: marks jd. Cancer Res. 1998 Feb 1;58(3):485-90. Cancer Res. 1998. PMID: 9458094

7

Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu.

Adams GP, Schier R, McCall AM, Crawford RS, Wolf EJ, Weiner LM, Marks JD. Adams GP, et al. Among authors: marks jd. Br J Cancer. 1998 May;77(9):1405-12. doi: 10.1038/bjc.1998.233. Br J Cancer. 1998. PMID: 9652755 Free PMC article.

8

Isolation and characterization of an anti-CD16 single-chain Fv fragment and construction of an anti-HER2/neu/anti-CD16 bispecific scFv that triggers CD16-dependent tumor cytolysis.

McCall AM, Adams GP, Amoroso AR, Nielsen UB, Zhang L, Horak E, Simmons H, Schier R, Marks JD, Weiner LM. McCall AM, et al. Among authors: marks jd. Mol Immunol. 1999 May;36(7):433-45. doi: 10.1016/s0161-5890(99)00057-7. Mol Immunol. 1999. PMID: 10449096

9

Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity.

Nielsen UB, Adams GP, Weiner LM, Marks JD. Nielsen UB, et al. Among authors: marks jd. Cancer Res. 2000 Nov 15;60(22):6434-40. Cancer Res. 2000. PMID: 11103810

10

High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules.

Adams GP, Schier R, McCall AM, Simmons HH, Horak EM, Alpaugh RK, Marks JD, Weiner LM. Adams GP, et al. Among authors: marks jd. Cancer Res. 2001 Jun 15;61(12):4750-5. Cancer Res. 2001. PMID: 11406547

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

297 results

Search Page

Filters